Tiger Brokers

BUZZ-Summit Therapeutics rises on clinical trial collaboration with Pfizer

Reuters
Feb 24
BUZZ-Summit <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises on clinical trial collaboration with Pfizer

** Shares of drug developer Summit Therapeutics SMMT.O rise 6.2% to $23.50 premarket

** Co says it is collaborating with Pfizer PFE.N to study its experimental drug ivonescimab in combination with several of Pfizer's targeted cancer therapies called antibody drug conjugates (ADCs) across different types of tumors

** Under the agreement, SMMT will provide ivonescimab for the studies, which PFE will conduct

** Studies expected to start mid-year

** SMMT's drug has previously showed better survival rates in some lung cancer patients in a trial in China, outdoing Merck's MRK.N blockbuster Keytruda

** Stock has risen 5x in the last 12 months after outperforming Keytruda - the world's biggest drug with more than $29 billion in sales last year - in those studies

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10